Fletcher Robert S sold $50K of SYK

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

Stryker (NYSE) agreed to acquire ZuriMED, a private Swiss developer of rotator cuff augmentation tech. The deal aims to bolster Stryker's shoulder care portfolio, addressing a key clinical need. ZuriMED was spun off from Swiss universities in 2015.

Stryker Corporation (SYK) hit a 52-week low after its CFO highlighted challenges in the vascular segment. GF Value™ estimates SYK is 33.5% undervalued at $277.60, with a GF Score™ of 94. Insider selling totaled $586.1M over 12 months, while 11 gurus have mixed positions. SYK's P/E ratio is 28.77x, below its 5-year median of 42.11x.

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.

Stryker shares dropped 7.7% on Tuesday due to ongoing supply chain issues and weaker-than-expected joint replacement sales. CFO Preston Wells stated that manufacturing problems will persist into Q4, impacting sales growth. The company also missed recovery expectations in its joint replacement business, citing seasonal weakness. Investors are concerned about the timing of a broader recovery.

Stryker (SYK) shares fell to a 52-week low after its CFO discussed challenges in vascular and orthopedics segments at the 2026 Wells Fargo Healthcare Conference. Rival Zimmer Biomet (ZBH) also saw a decline.